This week the headline appeared to have some tough news for RNA companies, but Alnylam remains undeterred about the potential of its treatments.» Read More
If you’ve got $10,000 for investment, here’s how Cramer would put that money to work, right here and right now.
March 12- The number of U.S. cattle deaths that may be linked to the Merck& Co Inc feed additive Zilmax are much higher than the figures reported by the drug company to the federal government, according to a research study published on Wednesday.
March 10- Germany has granted Northwest Biotherapeutics Inc special permission to sell its experimental brain cancer drug in the country, the company said, and its stock jumped as much as 36 percent.
March 10- German health regulators have granted Northwest Biotherapeutics Inc special permission to sell its experimental brain cancer drug, DCVax-L, in the country, even though the small U.S. biotechnology company has not yet completed its late-stage trial of the immunotherapy.
Several insurers, including Molina Healthcare, which administer health plans for California's Medicaid program for the poor are asking states to step in and pay for Gilead Sciences Inc's Sovaldi, a drug that costs $84,000 per patient.
New pill treatments show better cure rates and fewer side effects. Here are the companies behind those therapies.
*Men's Wearhouse raises offer for Jos. Gains were broad, with nine of the 10 S&P 500 sectors up on the day and a number of bellwethers, including Caterpillar Inc and Merck& Co, hitting 52- week highs.
*Insurance stocks rise after Humana comments. *Men's Wearhouse raises offer for Jos. Gains were broad, with nine of the 10 S&P 500 sectors up on the day and a number of bellwethers, including Caterpillar Inc and Merck& Co, hitting 52- week highs.
Before you put your next dollar in stocks, Cramer would like a word about cyclical versus secular stocks.
Check out which companies are making headlines after the bell Wednesday.
NEW YORK/ LONDON, Feb 19- A handful of consumer and healthcare companies including Bayer AG and Novartis are exploring a deal for Merck& Co Inc's consumer healthcare business, as they seek to gain scale in a fragmented industry, according to several people familiar with the matter.
With correlation levels back to where they were before the financial crisis, investors are embracing the stock picker's market.
Feb 18- Actavis Plc is in advanced talks to acquire rival drug maker Forest Laboratories Inc in a deal that could value Forest at up to $25 billion, the Wall Street Journal reported citing people familiar with the matter. Actavis competes with larger drugmakers such as Teva Pharmaceuticals Industries Ltd and Mylan Inc..
Some of the names on the move ahead of the open.
LONDON, Feb 12- Consumer goods group Reckitt Benckiser reported a rise in sales and forecast further growth this year despite challenges in emerging markets and named a new chairman for its declining pharmaceuticals business to help with a strategic review.
LONDON, Feb 12- Reckitt Benckiser Group said on Wednesday the strategic review of its pharmaceuticals business was ongoing and that it would update investors over the course of the year. The company said in October it was considering all options for the business, which could include selling it, spinning it off, or keeping it.
Some of Friday's midday movers:
Feb 7- Merck& Co said on Friday it will pay $100 million to resolve all U.S. product liability lawsuits alleging it downplayed serious health risks involving its NuvaRing intrauterine contraceptive device.
Feb 7- Merck& Co said on Friday it has agreed to pay $100 million to resolve all U.S. product liability lawsuits involving its NuvaRing contraceptive product.
Feb 6- Merck& Co has agreed to pay $100 million to settle hundreds of lawsuits accusing the U.S. drugmaker of downplaying serious health risks associated with its NuvaRing contraceptive device, Bloomberg reported on Thursday, citing people familiar with the deal.